Virtual Library
Start Your Search
M. Davidescu
Author of
-
+
P3.16 - Surgery (ID 732)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Surgery
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.16-018 - Null 30-Days Mortality After 72 Consecutive Left Open Pneumonectomies for Lung Cancer (ID 10012)
09:30 - 09:30 | Author(s): M. Davidescu
- Abstract
Background:
The authors evaluate the 30-days mortality after open pneumonectomy for lung cancer and compare the results obtained for left-right pneumonectomy.
Method:
Between 2008 and 2011 there were radically resected 326 consecutive cases of lung cancer. There were 117 pneumonectomies – 72 on left and 45 on right, all performed through thoracotomy.
Result:
Overall 30-days mortality rate was 3,41% after pneumonectomy for lung cancer. After left pneumonectomy there was 0% mortality and after right pneumonectomy - 8,88% mortality. In 37 cases the patients received induction therapy – on those cases the mortality was 2,7% at 30 days, meaning 5% for right and 0% for left pneumonectomies. Without induction therapy the 80 patients operated per primam presented 3,75% 30-days mortality (12% for right and 0% for left pneumonectomies). These values are excellent for left pneumonectomies and similar to the literature for the right ones. The case selection is not the “cause of success” since 40,17% of cases were pathological stage III (TNM 6-th edition - valid at that time) and 29,05% were pathological stage II. Neither the limitation of the resection affected the mortality since the authors have performed 64,1% of pneumonectomies (75 cases) with intrapericardial approach, of which 21 pericardiectomies, 17 pericardioplasties and 3 atrial resections. All resection included mediastinal lymph node dissection. From best of our knowledge mediastinal lymph node dissection doesn’t affect 30-days mortality after pneumonectomy for lung cancer.
Conclusion:
A null mortality rate at 30-days after left pneumonectomy for lung cancer is possible, without case selection.